Lexaria Bioscience (LEXX) Stock Overview
Operates as a biotechnology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LEXX Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Lexaria Bioscience Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.95 |
| 52 Week High | US$4.38 |
| 52 Week Low | US$0.79 |
| Beta | 0.89 |
| 1 Month Change | -1.51% |
| 3 Month Change | -31.98% |
| 1 Year Change | -65.37% |
| 3 Year Change | -66.23% |
| 5 Year Change | -91.73% |
| Change since IPO | -71.11% |
Recent News & Updates
Shareholder Returns
| LEXX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.3% | -1.1% | 1.0% |
| 1Y | -65.4% | -10.0% | 15.0% |
Return vs Industry: LEXX underperformed the US Pharmaceuticals industry which returned -10% over the past year.
Return vs Market: LEXX underperformed the US Market which returned 15% over the past year.
Price Volatility
| LEXX volatility | |
|---|---|
| LEXX Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LEXX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LEXX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 7 | Rich Christopher | lexariabioscience.com |
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company’s DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids.
Lexaria Bioscience Corp. Fundamentals Summary
| LEXX fundamental statistics | |
|---|---|
| Market cap | US$18.49m |
| Earnings (TTM) | -US$11.39m |
| Revenue (TTM) | US$615.92k |
Is LEXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LEXX income statement (TTM) | |
|---|---|
| Revenue | US$615.92k |
| Cost of Revenue | US$2.72k |
| Gross Profit | US$613.20k |
| Other Expenses | US$12.00m |
| Earnings | -US$11.39m |
Last Reported Earnings
May 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 99.56% |
| Net Profit Margin | -1,849.39% |
| Debt/Equity Ratio | 0% |
How did LEXX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/20 01:23 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2025/05/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lexaria Bioscience Corp. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ammar Shah | Eight Capital |
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |